EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Single-Arm Trial of EBV-Specific TCR-T Cells With Anti-PD1 Auto-secreted Element in the Treatment of EBV-Positive Head and Neck Carcinoma
Sponsor: TCRCure Biopharma Ltd.
Listed as NCT04139057, this PHASE1/PHASE2 trial focuses on Head and Neck Squamous Cell Carcinoma and remains completed. Sponsored by TCRCure Biopharma Ltd., it has been updated 12 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1/PHASE2
Status: Recruiting → Completed
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 7 earlier versions
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting
-
Dec 2022 — Mar 2023 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jan 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2019 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TCRCure Biopharma Ltd.
- Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .